Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 25;11:527750. doi: 10.3389/fimmu.2020.527750

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Cai, Duan, Qian, Wang, Wang, Li, Wang, Zhao, Zhang, Bai and Wang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effect of ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion and G2032R mutation resistance on programmed death-ligand 1 (PD-L1) expression. (A) Analysis of Ba/F3, Ba/F3 ROS1 fusion and Ba/F3 ROS1 G2032R crizotinib resistant characteristics by CCK8; (B) Flow cytometric analysis of PD-L1 surface expression in Ba/F3, ROS1 fusion, and ROS1 G2032R mutation resistance cell lines; (C) Flow cytometric analysis of PD-L1 surface expression in Ba/F3, ROS1 fusion, and ROS1 G2032R mutation resistant cell lines; (D) The protein expression of PD-L1 in ROS1 fusion and ROS1 G2032R mutation resistant cell lines after treatment with crizotinib; (E) PD-L1 expression after ROS1 inhibition by crizotinib, Lorlatinib, and TPX-0005 at 1 μM for 6 h or SHP2 (10 μM) by SHP099 for 10 h. Red line represents control group and Green line represents treatment group.